QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow

Published on 24 Jan 2023 on Zacks via Yahoo Finance

QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow

QIAGEN N.V. QGEN recently announced the launch of EZ2 Connect MDx for use in diagnostic laboratories. This makes the in-vitro devices (IVD) platform for automated sample processing available for widescale use 18 months after being made available for research.

EZ2 Connect MDx complements QIAGEN’s automated IVD nucleic extraction platforms, which includes QIAcube Connect MDx and QIAsymphony. The device now carries the European Union’s (EU) CE-IVD compliance marking for IVD for the EU and other countries that accept this designation. It is also available in the United States, Canada and other countries.

QIAGEN has placed more than 5,000 EZ1 and EZ2 instruments worldwide through the end of 2022.

Read the rest of the article

NYSE.AMN price evolution

NASDAQ.MMSI price evolution

NYSE.CAH price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

News

QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow

NYSE.AMN price evolution

NASDAQ.MMSI price evolution

NYSE.CAH price evolution

Want to become a better investor?

With 89% institutional ownership, Cardinal Health, Inc. (NYSE:CAH) is a favorite amongst the big...

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

Here's Why You Should Retain Medtronic (MDT) Stock for Now

GE HealthCare (GEHC), RSNA Unite to Aid Breast Cancer Imaging

Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up

S&P 500 (SPX) today: Top movers are Caesars Entertainment Corp and Cardinal Health Inc

Reasons to Hold The Cooper Companies (COO) in Your Portfolio Now

QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing

Cardinal Health, Inc. (CAH) is Attracting Investor Attention: Here is What You Should Know

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio